Kangmei Pharmaceutical: Intends to transfer 100% equity of Dongyang Kangmei for no less than RMB 49.7827 million.

Kangenbei announced that, in order to revitalize existing assets and focus on core business, the company plans to transfer 100% equity of Dongyang Kangenbei at a listed price of not less than 49.7827 million yuan through the Zhejiang Property Rights Exchange. As of December 31, 2025, the assessed value of all equity of Dongyang Kangenbei shareholders is 52.7827 million yuan, and a cash dividend of 3 million yuan for the year 2025 has been implemented in May 2026. If a buyer is successfully solicited and the transfer is completed, it is estimated that a transfer profit of over 8 million yuan will be realized. If a qualified buyer is not solicited by the end of the listing period, there is a risk that the transfer may not be completed.